Positive clinical data supports BrainsWay's scientific narrative and could drive adoption among clinicians treating MDD with suicidal ideation. However, the lack of FDA clearance for this specific indication limits immediate commercial impact. Monitor for any future FDA submission or label expansion announcements. The 20-F (filed April 2026) showed strong revenue growth of 27% to $52.2M, providing fundamental support alongside this clinical catalyst.
Price Chart
Executive Summary
BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70% relative reduction in suicidal ideation among MDD patients treated with Deep TMS (from 22.5% to 6.7% over 6 weeks). The data adds to a growing body of 2026 research supporting Deep TMS for suicidality, though the device is not FDA-cleared for this indication. The filing is a clinical-data update without financial figures, providing incremental positive evidence for label expansion potential.
Key Facts
- 70% relative reduction in patients with suicidal ideation (SSI>0) from 22.5% at baseline to 6.7% after 6 weeks of Deep TMS
- Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol vs 13 days with standard protocol (statistically significant)
- Data published in Journal of Affective Disorders as secondary analysis of prior multisite randomized trial that supported FDA clearance of SWIFT in September 2025
- Deep TMS is not FDA-cleared for treatment or prevention of suicidal ideation or behavior
Financial Impact
No financial figures provided; potential label expansion catalyst for Deep TMS in MDD, which could expand addressable market if future FDA clearance obtained
Risk Factors
- Secondary analysis data, not a prospective randomized trial designed for suicidality endpoint
- Deep TMS not FDA-cleared for suicidal ideation — no near-term label expansion
- Small sample size (89 patients) limits statistical robustness
- Historical performance shows mixed T+20 outcomes on prior bullish reports for BWAY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005759 |
| Document: 0001171843-26-005759-index-headers.html | 0001171843-26-005759 |
| Document: 0001171843-26-005759-index.html | 0001171843-26-005759 |
| Document: 0001171843-26-005759.txt | 0001171843-26-005759 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access